Section XIV 1/23

Senior-supervisors within the doctoral studies at the MUV Name of supervisor (LAST NAME, First name): LANZENBERGER Rupert Organizational unit & subunit: Department of Psychiatry & Psychotherapy / Biolog. Psychiatry, Neuroimaging Lab Studies (N094, N790): N094 Thematic Program: Medical Imaging Funding source for students to be supervised: Third-party funding (select a max. of 5 starting with the most recent), PI:

Period Organization (eg. FWF) Short title €

2014-17 FWF Effects of Electroconvulsive Therapy on

Monoamine Oxidase A distribution volume in

treatment-resistant depression (PI)

282,344

2011-15 FWF The Norepinephrine Transporter in Attention

Deficit Hyperactivity Disorder investigated

with PET. (PI)

162,208

2012-16 FWF Influence of light exposure on cerebral

Monoamine oxidase A in Seasonal Affective

Disorder and Healthy Controls (Co-PI)

263,650

2011-14 FWF Effects of sex steroid hormones on human

brain function, structure and connectivity: A

longitudinal study using 7 Tesla Ultrahigh-

field Magnetic Resonance Imaging (PI)

292,135

2010-13 NARSAD / USA Effects of electroconvulsive therapy on 5-HT-

1A receptor binding in depression (PI)

~44,400

Local, national and international co-operations (select a max. of 5 starting with the most recent)

Name (Last-, Firstname) Title of project

VOLKOW Nora, NIDA, USA The Norepinephrine Transporter in Attention Deficit

Hyperactivity Disorder investigated with PET.

SWAAB Dick F, Netherlands Effects of sex steroid hormones on human brain function,

Section XIV 2/23

structure and connectivity: A longitudinal study using 7 Tesla

Ultrahigh-field Magnetic Resonance Imaging

LAMM Claus, UniVie,

Austria

Multimodal Assessment of Neurobiological Markers for

Psychiatric Disorders (MAN-BIOPSY), Interuniversitary Cluster

COMASCO Erika, Sweden Functional MRI in premenstrual dysphoric disorder

Terman Michael, Columbia,

NY, USA

Influence of light exposure on cerebral Monoamine oxidase A

in Seasonal Affective Disorder and Healthy Controls measured

by PET Current doctoral students

Name (Last-, Firstname) Title of project

Stein Patrycja, MD The influence of hormone replacement therapy on the

cerebral serotonin-1A receptor distribution and mood in post-

menopausal women (N790, CLINS)

Kraus Christoph, MD Serotonin and Neuroplasticity – Investigated in vivo by

Positron Emission Tomography and structural Magnetic

Resonance Imaging (N790, CLINS)

Baldinger Pia, MD Influence of genetic variants on serotonergic

neurotransmission (N790, CLINS)

Vanicek Thomas, MD Molecular imaging in adult attention deficit/hyperactivity

disorder (N790, CLINS)

Gryglewski Gregor Multimodal imaging to predict brain activation patterns during

pharmacological challenges combining neuroreceptor PET Former doctoral students (select a max. of 5 starting with the most recent)

Name (Last-, Firstname) Title of the doctoral thesis

Hahn Andreas, Dr. MSc N790: Optimized non-invasive quantification of neuronal

receptors in healthy condition and psychiatric disorders using

positron emission tomography (N790, CLINS)

Hahn Andreas, Dr. MSc N790: Optimized non-invasive quantification of neuronal

receptors in healthy condition and psychiatric disorders using

positron emission tomography (N790, CLINS)

Savli Markus, Dr.techn.DI Higher order principles in distribution patterns of serotonergic

receptor subtypes revealed by positron emission tomography

Spindelegger Christoph, MD Effects of progesterone and estradiol on the human

serotonergic neurotransmission

Stein Patrycja, MD Sex differences in the serotonin-1A receptor distribution of the

Section XIV 3/23

human brain measured by positron emission tomography Former diploma students (select a max. of 5 starting with the most recent)

Name (Last-, Firstname) Title of the diploma thesis

Cotton Marian, MD Uptake of the NET-specific PET radioligand (S,S)-

[18F]FMeNER-D2 in the human head

Lipskaia Natalia, MD Short-term changes in gray matter volume after i.v. ketamine

administration in healthy volunteers measured with 3 Tesla

MRI

James Gregory Mag. In-vivo serotonin transporter quantification using positron

emission tomography and reference tissue kinetic modelling

implemented in Matlab

Fischer Michaela The effects of sex steroid hormones on empathy investigated

with the Reading-the-Mind-in-the Eyes-Test

Nemeth Daniela Influence of gonadal hormones on thermal sensitivity under

cross sex hormone treatment in transsexuals. Other supervisions (select a max. of 5 starting with the most recent)

Name (Last-, Firstname) Kind of Supervision

Sladky Ronald, Dr.Mag. Thesis in Medical Physics (N094), Mentor

Gong Yao, MD PhD Thesis in Clinical Endocrinology, Metabolism (N790), Mentor

Beiranvand Farahnaz, MSc N094, Mentor

Zeilinger Markus, MSc N790, Mentor

Weber Corinna N790, Mentor Publications with trained and supervised individuals as listed above as first-authors (reference all authors and provide the exact citation; the name of the applicant in bold letters; corresponding author underlined; e.g.: O'Connor V, El Far O, Bofill-Cardona E, Nanoff C, Freissmuth M,

Karschin A, Airas JM, Betz H, Boehm S. Science. 1999 Nov 5;286(5442):1180-4.) 1. Vanicek T*, Spies M*, Rami-Mark C, Savli M, Höflich A, Kranz GS, Hahn A,

Kutzelnigg A, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Volkow N, Kasper S, Lanzenberger R. (*contributed equally) The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography. JAMA Psychiatry 2014 Dec 1;71(12):1340-9. Epub 2014 Oct 22 [2013, IF: 13.747]

2. Hahn A, Wadsak W, Windischberger C, Baldinger P, Höflich A, Losak J, Nics L, Philippe C, Kranz GS, Kraus C, Mitterhauser M, Karanikas G, Kasper S, Lanzenberger R. Differential modulation of the default mode network via serotonin-1A receptors.

Section XIV 4/23

Proceedings of the National Academy of Sciences USA (PNAS) 2012 Feb 14;109(7):2619-24. Epub 2012 Jan 30 [2013, IF: 9.809]

3. Kranz G, Hahn A, Savli M, Lanzenberger R. Challenges in the differentiation of midbrain raphe nuclei in neuroimaging research. Proceedings of the National Academy of Sciences USA (PNAS) 2012 Jul 17;109(29):E2000. Epub 2012 Jun 18 [2013, IF: 9.809]

4. Kranz GS, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, Haeusler D,

Spies M, Mitterhauser M, Kasper S, Lanzenberger R. High-dose testosterone treatment increases serotonin transporter binding in transgender people. Biological Psychiatry 2014 xxx. Epub 2014 Sep 23 [2013, IF: 9.472]

5. Hahn A, Kranz GS, Küblböck M, Kaufmann U, Ganger S, Hummer A, Seiger R, Spies

M, Winkler D, Kasper S, Windischberger C, Swaab DF, Lanzenberger R. Structural connectivity networks of transgender people. Cerebral Cortex 2014 xxx. Epub 2014 Sep 12. [2013, IF: 8.305]

6. Hahn A, Haeusler D, Kraus C, Höflich A, Kranz GS, Baldinger P, Savli M, Mitterhauser M, Wadsak W, Karanikas G, Kasper S, Lanzenberger R. Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression. Human Brain Mapping 2014 Aug;35(8):3857-66. Epub 2014 Jan 17. [2013, IF: 6.924]

7. Kranz GS, Hahn A, Kaufmann U, Küblböck M, Hummer A, Ganger S, Seiger R,

Winkler D, Swaab DF, Windischberger C, Kasper S, Lanzenberger R. White matter microstructure in transsexuals and controls investigated by diffusion tensor imaging. Journal of Neuroscience 2014 Nov 12; 34(46):15466 –15475 [2013, IF: 6.747]

8. Baldinger P*, Kraus C*, Rami-Mark C, Gryglewsky G, Kranz GS, Haeusler D, Hahn A, Spies M, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R (*contributed equally) Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding. NeuroImage 2015 xxx. Epub 2015 Jan 31 [2013, IF: 6.132]

9. Kraus C, Ganger S, Losak J, Hahn A, Savli M, Kranz GS, Baldinger P,

Windischberger C, Kasper S, Lanzenberger R. Gray matter and intrinsic network changes in the posterior cingulate cortex after selective serotonin reuptake inhibitor intake. NeuroImage 2014 Jan;84(x):236-244. Epub 2013 Aug 26 [2013, IF: 6.132]

10. Hahn A, Kranz GS, Seidel EM, Sladky R, Kraus C, Küblböck M, Pfabigan DM, Hummer A, Grahl A, Ganger S, Windischberger C, Lamm C, Lanzenberger R. Comparing neural response to painful electrical stimulation with functional MRI at 3 and 7 T NeuroImage 2013 Nov 15;82:336-343. Epub 2013 Jun 12 [2013, IF: 6.132]

11. Kraus C, Hahn A, Savli M, Kranz GS, Baldinger P, Höflich A, Spindelegger C,

Ungersboeck J, Haeusler D, Mitterhauser M, Windischberger C, Wadsak W, Kasper S, Lanzenberger R.

Section XIV 5/23

Serotonin-1A receptor binding is positively associated gray matter volume – A multimodal neuroimaging study combining PET and structural MRI. Neuroimage 2012 Nov 15;63(3):1091-1098. Epub 2012 Jul 23 [2013, IF: 6.132]

12. Savli M, Bauer A, Mitterhauser M, Ding Y.S, Hahn A, Kroll T, Neumeister A, Haeusler

D, Ungersboeck J, Henry S, Isfahani SA, Rattay F, Wadsak W, Kasper S, Lanzenberger R. Normative database of the serotonergic system in healthy subjects using multi-tracer PET. Neuroimage 2012 Oct 15;63(1):447-59. Epub 2012 Jul 10 [2013, IF: 6.132]

13. Hahn A, Nics L, Baldinger P, Ungersböck J, Dolliner P, Frey R, Birkfellner W,

Mitterhauser M, Wadsak W, Karanikas G, Kasper S, Lanzenberger R. Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl-11C]WAY-100635 independent of arterial sampling. Neuroimage 2012 Aug 1;62(1):199-206. Epub 2012 May 2. [2013, IF: 6.132]

14. Hahn A*, Stein P*, Windischberger C, Weissenbacher A, Gerstl F, Moser E, Kasper S, Lanzenberger R. (*contributed equally) Reduced resting state functional connectivity between amygdala and orbitofrontal cortex in social anxiety disorder. NeuroImage 2011 Jun 1;56(3):881-9. Epub 2011 Feb 26. [2013, IF: 6.132]

15. Stein P, Baldinger P, Kaufmann U, Rami-Mark C, Hahn A, Höflich A, Kranz GS, Savli

M, Wadsak W, Mitterhauser M, Winkler D, Kasper S, Lanzenberger R. Relation of progesterone and DHEAS serum levels to 5-HT1A receptor binding potential in pre- and postmenopausal women. Psychoneuroendocrinology 2014 Aug;46:52-63. Epub 2014 May 10 [2013, IF: 5.591]

16. Kranz GS, Rami-Mark C, Kaufmann U, Baldinger P, Hahn A, Höflich A, Savli M, Stein P, Wadsak W, Mitterhauser M, Winkler D, Lanzenberger R#, Kasper S. Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl-11C]WAY-100635. (#corresponding author) Psychoneuroendocrinology 2014 July;45:1-10. Epub 2014 March 20 [2013, IF: 5.591]

17. Gryglewski G, Lanzenberger R#, Kranz GS, Cumming P. (#corresponding author). Molecular Imaging: Serotonin transporters are reduced in major depression. Journal of Cerebral Blood Flow & Metabolism 2014 Jul;34(7):1096-103. Epub 2014 May 7 [2013, IF: 5.339]

18. Stein P, Savli M, Wadsak W, Mitterhauser M, Fink M, Spindelegger C, Mien LK,

Moser U, Dudczak R, Kletter K, Kasper S, Lanzenberger R. The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-11C]WAY-100635. European Journal of Nuclear Medicine and Molecular Imaging (Eur J Nucl Med Mol Imaging) 2008 Dec;35(12):2159-68. Epub 2008 Jun 10. [2013, IF: 5.217]

19. Baldinger P, Hahn A, Mitterhauser M, Kranz G, Friedl M, Wadsak W, Kraus C,

Ungersböck J, Hartmann A, Giegling I, Rujescu D, Kasper S, Lanzenberger R. Impact of COMT genotype on serotonin-1A receptor binding investigated with PET.

Section XIV 6/23

Brain Structure and Function 2014;219:2017–2028. Epub 2013 Aug 9. [2013, IF: 4.567]

20. Kranz GS, Hahn A, Baldinger P, Haeusler D, Philippe C, Kaufmann U, Wadsak W,

Savli M, Höflich A, Kraus C, Vanicek T, Mitterhauser M, Kasper S, Lanzenberger R. Cerebral serotonin transporter asymmetry in females, males and male-to-memale transsexuals measured by PET in vivo. Brain Structure and Function 2014 Jan;219(1):171-83. Epub 2012 Dec 9. [2013, IF: 4.567]

21. Spindelegger C, Stein P, Wadsak W, Fink M, Mitterhauser M, Moser U, Savli M, Mien LH, Akimova E, Hahn A, Willeit M, Kletter K, Kasper S, Lanzenberger R. Light-dependent alteration of serotonin-1A receptor binding in cortical and subcortical limbic regions in the human brain. World Journal of Biological Psychiatry 2012 Sept;13(6):413-422. Epub 2011 Nov 23 [2013, IF: 4.225]

22. Kraus C, Baldinger P, Rami-Mark C, Gryglewski G, Kranz GS, Haeusler D, Hahn A,

Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Exploration the impact of BDNF Val66Met genotype on serotonin transporter and serotonin-1A receptor binding. PLoS ONE 2014 xx.x. Epub 2014 Sep 4;9(9). [2013, IF: 3.534]

23. Kranz GS, Kasper S, Lanzenberger R.

Reward and the Serotonergic System. (REVIEW) Neuroscience 2010 Apr 14;166(4):1023-1035. Epub 2010 Jan 28. [2013, IF: 3.327]

24. Hahn A, Nics L, Baldinger P, Wadsak W, Savli M, Kraus C, Birkfellner W,

Ungersboeck J, Haeusler D, Mitterhauser M, Karanikas G, Kasper S, Frey R, Lanzenberger R. Application of image-derived and venous input functions in major depression using [carbonyl-11C]WAY-100635. Nuclear Medicine and Biology 2013 Apr; 40(3): 371-7; Epub 2013 Jan 30 [2013, IF: 2.408].

25. Baldinger P, Lotan A, Frey R, Kasper S, Lerer B, Lanzenberger R. Neurotransmitters and ECT

30.2 Special Issue: Mechanism of Action of ECT (Pascal Sienaert, guest-editor) Journal of ECT 2014 Jun;30(2):116-21. Epub 2014 May 9 [2013, IF: 1.387]

Section XIV 7/23

Headline and description of the planned project: Effects of electroconvulsive therapy on monoamine oxidase A distribution volume in treatment-resistant depression investigated with PET. (FWF P 27141) BACKGROUND & AIM OF THE STUDY In treatment-resistant depression, electroconvulsive therapy (ECT) has been shown to effectively reduce depressive symptoms; however, the underlying neurobiological mechanisms remain to be fully understood. Recent neuroimaging findings underline the involvement of the serotonergic system in the mechanism of action of ECT, but studies in this context mainly focused on serotonin receptor and the serotonin transporter. Here, the aim of the study is to assess the effects ECT on monoamine oxidase A (MAO-A), the main serotonin degrading enzyme which is known to be involved in antidepressant action, in humans using positron emission tomography (PET) and the radiotracer [11C]harmine. Moreover, as the antidepressant effects of electroconvulsive stimulations were shown to be partly mediated via changes in neuroplasticity, a secondary aim of the present study is to assess structural alterations caused by ECT using magnetic resonance imaging (sMRI). HYPOTHESES AND MAIN OUTCOME 1. Upon completion of the ECT series, the overall MAO-A distribution volumes (DVs) in the

brain of depressed patients will change significantly. 2. At baseline, MAO-A DVs of depressed patients will be higher than MAO-A DVs of healthy

subjects. 3. There will be a significant difference in MAO-A DVs change in responders (reduction in

Hamilton Rating Scale of Depression (HAM-D) scores by 50%) compared to non-responders.

4. Upon completion of the ECT series, there will be significant structural changes measured by sMRI.

5. At baseline, grey matter volume of depressed patients will significantly differ from healthy subjects.

6. Treatment associated changes in MAO-A DVs will be associated with structural grey matter changes.

7. Changes in the MAO-A DVs/GMV will correlate with a decrease in depressive symptoms as assessed using HAM-D scores.

METHODS Outcome measures: The main outcome measure of the study is the change in MAO-A distribution volume induced by a treatment course of 6 to 14 ECTs (ECT series) and comparing depressed patients versus healthy subjects before ECT. The secondary outcome measure of the study is the change in grey matter volume caused by ECT in depressed patients. A decrease in the HAM-D scores of at least 50% serves as measure for therapeutic efficacy of the ECT. Study design: longitudinal mono-centre study Study duration: 36 months Study population: 18 subjects with therapy-resistant, severe unipolar depression, age 18-60 years and 18 age- and sex-matched healthy subjects. Medication: Psychotropic medication (except for drugs directly binding MAO-A, e.g. moclobemid) is allowed if steady state has been reached > 10 days prior to inclusion. Measurements: Each patient will be measured three times using a GE Advance PET scanner and the radioligand [11C]harmine. The first and second measurements determine baseline changes in the MAO-A DVs while the third scan is used to quantify changes induced by ECT. Healthy subjects will be measured with PET only once. Similarly, patients will undergo three structural (T1-weighted) MRI sessions temporally coordinated to the PET scans. Healthy subjects will be measured with MRI only once.

Section XIV 8/23

ECT: Each patient will be treated in 6 to 14 ECT sessions within a time interval of 2 to 5 weeks. A brief pulse ECT machine (Thymatron System IVTM) will be used three times per week to administer treatments either unilaterally over the right hemisphere or, if required, bilaterally. Data analysis: The MAO-A DVs will be determined using a region of interest and a whole brain voxel-wise approach. A repeated-measures analysis of variance (ANOVA) will compare the change in the MAO-A DVs before and after ECT (PET2-PET3) with the change between the baseline PET scans (PET1-PET2). Secondly, MAO-A DVs from PET1 will be compared to the scans of healthy subjects (cross-sectional part). Additionally, the correlation between treatment effects reflected in HAM-D score and changes in MAO-A DVs will be computed. Similar statistical analyses will be done with sMRI data. RELEVANCE and POTENTIAL IMPLICATIONS of this study: This study would be the first to demonstrate an effect of ECT on MAO-A DVs in humans in vivo. Given the involvement of the MAO-A in the pathophysiology of mood disorders, the present study would be an important step towards a better understanding of antidepressant treatment and treatment response. By comparing treatment effects and the underlying biological mechanism, the study might help to identify biomarkers that distinguish patients who are likely to benefit from ECT from patients who will rather be non-responders. Finally, by investigating the role of the MAO-A DVs in ECT, its highly discussed relevance for antidepressant action will be further elucidated and might prepare the ground for new therapeutic strategies. Additionally, this study might contribute in substantiating potential effects of ECT on brain structure.

Section XIV 9/23

Curriculum Vitae

Name: Rupert Lanzenberger, Assoc.Prof. PD Dr.med. Address Kaiserstrasse 1070 Wien Personal Data Date of Birth: 22.12.1964Place of Birth: Scheibbs / AustriaNationality Austria

Education 2010 Habilitation in Neurosciences2005-2015 Doctoral Program (Dr.rer.nat.), University of Vienna 1998 M.D. degree, Medical School, University of Vienna

Career History 2012, July appointed as Associate Professor, MedUni Wien, Austria2015 – present Head, EEG Lab, Department of Psychiatry &

Psychotherapy, MedUni. 2014 – present Speaker, IG Neuroimaging, Medical Neurosciences Cluster

(MNC), MedUni. 2013 – present Head, Chemical Lab, Department of Psychiatry &

Psychotherapy, MedUni. 2013 – present Speaker, Quantitative Clinical Imaging (QCI) Node,

Medical Imaging Cluster (MIC) 2011 – present Speaker, Research Cluster between Medical University &

University of Vienna (Multimodal Neuroimaging in Clinical Neurosciences – Assessment of neurobiological markers for psychiatric disorders).

2008 – present Co-Coordinator PhD program CLINICAL NEUROSCIENCES (CLINS) N790

2005 – present Head, Neuroimaging Lab – PET & MRI, Department of Psychiatry & Psychotherapy.

2010 – 2012 appointed as Assistant Professor, MedUni Wien 2004 – 2005 Postdoctoral Research Fellow in the Neuroimaging Group

at the Department of General Psychiatry, MedUni. 1999 – 2003 Postdoctoral Research Fellow at the Ludwig Boltzmann

Institute for Functional Brain Topography, Department of Neurology, Medical School, University of Vienna

Section XIV 10/23

List of publications: Total: 123 Articles, cIF 539.9 (105 Original Articles, 18 Reviews); 3 Book Chapters Total Number of Citations: 2873/2020, H-Index: 29/23 (Google Scholar / Scopus) A. First or Senior / Corresponding Author (accumulated 2013 IF: 278.5; 50 papers;

mean IF: 5.6) 26. Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D,

Micskei Z. Stein P, Karanikas G, Wadsak W, Kasper S, Frey R. Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. Molecular Psychiatry 2013 Jan;18(1):93-100. Epub 2012 Jul 3 [2013, IF: 15.147]

Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, Micskei Z. Stein P, Karanikas G, Wadsak W, Kasper S, Frey R. Impact of electroconvulsive therapy on 5-HT1A receptor binding in major depression. Molecular Psychiatry 2013 Jan;18(1):1. IMAGE featured article [2013, IF: 15.147]

27. Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, Micskei Z. Stein P, Karanikas G, Wadsak W, Kasper S, Frey R. Impact of electroconvulsive therapy on 5-HT1A receptor binding in major depression. Molecular Psychiatry 2013 Jan;18(1):1. IMAGE featured article [2013, IF: 15.147]

28. Spindelegger C*, Lanzenberger R*, Wadsak W, Mien LK, Stein P, Mitterhauser M,

Moser U, Holik A, Pezawas L, Kletter K, Kasper S. (*contributed equally) Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders. Molecular Psychiatry 2009 Nov;14(11):1040-50. Epub 2008 Mar 25 [2013, IF: 15.147]

29. Vanicek T*, Spies M*, Rami-Mark C, Savli M, Höflich A, Kranz GS, Hahn A,

Kutzelnigg A, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Volkow N, Kasper S, Lanzenberger R. (*contributed equally) The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography. JAMA Psychiatry 2014 Dec 1;71(12):1340-9. Epub 2014 Oct 22 [2013, IF: 13.747]

30. Hahn A, Wadsak W, Windischberger C, Baldinger P, Höflich A, Losak J, Nics L, Philippe C, Kranz GS, Kraus C, Mitterhauser M, Karanikas G, Kasper S, Lanzenberger R. Differential modulation of the default mode network via serotonin-1A receptors. Proceedings of the National Academy of Sciences USA (PNAS) 2012 Feb 14;109(7):2619-24. Epub 2012 Jan 30 [2013, IF: 9.809]

31. Kranz G, Hahn A, Savli M, Lanzenberger R. Challenges in the differentiation of midbrain raphe nuclei in neuroimaging research. Proceedings of the National Academy of Sciences USA (PNAS) 2012 Jul 17;109(29):E2000. Epub 2012 Jun 18 [2013, IF: 9.809]

32. Lanzenberger R, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, Holik A, Attarbaschi T, Mossaheb N, Sacher J, Geiss-Granadia T, Kletter K, Kasper S, Tauscher J. Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder.

Section XIV 11/23

Biological Psychiatry 2007 May 1;61(9):1081-9. Epub 2006 Sep 18. [2013, IF: 9.472]

33. Kranz GS, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, Haeusler D, Spies M, Mitterhauser M, Kasper S, Lanzenberger R. High-dose testosterone treatment increases serotonin transporter binding in transgender people. Biological Psychiatry 2014 xxx. Epub 2014 Sep 23 [2013, IF: 9.472]

34. Kasper S, Kranz GS, Lanzenberger R. Testosterone, neural circuits and male depression. Commentary Biological Psychiatry 2014 Aug 15;76(4):272-273. [2013, IF: 9.472]

35. Hahn A, Kranz GS, Küblböck M, Kaufmann U, Ganger S, Hummer A, Seiger R, Spies

M, Winkler D, Kasper S, Windischberger C, Swaab DF, Lanzenberger R. Structural connectivity networks of transgender people. Cerebral Cortex 2014 xxx. Epub 2014 Sep 12. [2013, IF: 8.305]

36. Hahn A, Haeusler D, Kraus C, Höflich A, Kranz GS, Baldinger P, Savli M, Mitterhauser M, Wadsak W, Karanikas G, Kasper S, Lanzenberger R. Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression. Human Brain Mapping 2014 Aug;35(8):3857-66. Epub 2014 Jan 17. [2013, IF: 6.924]

37. Witte AV, Flöel A, Stein P, Savli M, Mien LK, Wadsak W, Spindelegger C, Moser U, Fink M, Hahn A, Mitterhauser M, Kletter K, Kasper S, Lanzenberger R Aggression is related to frontal serotonin-1A receptor distribution as revealed by PET in healthy subjects. Human Brain Mapping 2009 Aug;30(8): 2558-70. Epub 2008 Dec 11. [2013, IF: 6.924]

38. Kranz GS, Hahn A, Kaufmann U, Küblböck M, Hummer A, Ganger S, Seiger R, Winkler D, Swaab DF, Windischberger C, Kasper S, Lanzenberger R. White matter microstructure in transsexuals and controls investigated by diffusion tensor imaging. Journal of Neuroscience 2014 Nov 12; 34(46):15466 –15475 [2013, IF: 6.747]

39. Baldinger P*, Kraus C*, Rami-Mark C, Gryglewsky G, Kranz GS, Haeusler D, Hahn A, Spies M, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R (*contributed equally) Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding. NeuroImage 2015 xxx. Epub 2015 Jan 31 [2013, IF: 6.132]

40. Lanzenberger R, Kranz GS, Haeusler D, Akimova E, Savli M, Hahn A, Mitterhauser M, Spindelegger C, Philippe C, Fink M, Wadsak W, Karanikas G, Kasper S. Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. NeuroImage 2012 Nov 1;63(2):874-81. Epub 2012 Jul 22 [2013, IF: 6.132]

41. Kraus C, Ganger S, Losak J, Hahn A, Savli M, Kranz GS, Baldinger P, Windischberger C, Kasper S, Lanzenberger R. Gray matter and intrinsic network changes in the posterior cingulate cortex after selective serotonin reuptake inhibitor intake.

Section XIV 12/23

NeuroImage 2014 Jan;84(x):236-244. Epub 2013 Aug 26 [2013, IF: 6.132]

42. Hahn A, Kranz GS, Seidel EM, Sladky R, Kraus C, Küblböck M, Pfabigan DM, Hummer A, Grahl A, Ganger S, Windischberger C, Lamm C, Lanzenberger R. Comparing neural response to painful electrical stimulation with functional MRI at 3 and 7 T NeuroImage 2013 Nov 15;82:336-343. Epub 2013 Jun 12 [2013, IF: 6.132]

43. Höflich A, Savli M, Comasco E, Moser U, Novak K, Kasper S, Lanzenberger R. Neuropsychiatric deep brain stimulation for translational neuroimaging. NeuroImage 2013 Oct;79:30-41. Epub 2013 Apr 28 [2013, IF: 6.132]

44. Kraus C, Hahn A, Savli M, Kranz GS, Baldinger P, Höflich A, Spindelegger C, Ungersboeck J, Haeusler D, Mitterhauser M, Windischberger C, Wadsak W, Kasper S, Lanzenberger R. Serotonin-1A receptor binding is positively associated gray matter volume – A multimodal neuroimaging study combining PET and structural MRI. Neuroimage 2012 Nov 15;63(3):1091-1098. Epub 2012 Jul 23 [2013, IF: 6.132]

45. Savli M, Bauer A, Mitterhauser M, Ding Y.S, Hahn A, Kroll T, Neumeister A, Haeusler D, Ungersboeck J, Henry S, Isfahani SA, Rattay F, Wadsak W, Kasper S, Lanzenberger R. Normative database of the serotonergic system in healthy subjects using multi-tracer PET. Neuroimage 2012 Oct 15;63(1):447-59. Epub 2012 Jul 10 [2013, IF: 6.132]

46. Hahn A, Nics L, Baldinger P, Ungersböck J, Dolliner P, Frey R, Birkfellner W,

Mitterhauser M, Wadsak W, Karanikas G, Kasper S, Lanzenberger R. Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl-11C]WAY-100635 independent of arterial sampling. Neuroimage 2012 Aug 1;62(1):199-206. Epub 2012 May 2. [2013, IF: 6.132]

47. Hahn A*, Stein P*, Windischberger C, Weissenbacher A, Gerstl F, Moser E, Kasper S, Lanzenberger R. (*contributed equally) Reduced resting state functional connectivity between amygdala and orbitofrontal cortex in social anxiety disorder. NeuroImage 2011 Jun 1;56(3):881-9. Epub 2011 Feb 26. [2013, IF: 6.132]

48. Gerstl F, Windischberger C, Mitterhauser M, Wadsak W, Holik A, Kletter K, Moser E, Kasper S, Lanzenberger R. Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET. NeuroImage 2008 Jun;41(2):204-11. Epub 2008 Mar 6. [2013, IF: 6.132]

49. Fink M, Wadsak W, Savli M, Stein P, Moser U, Hahn A, Mien LK, Kletter K, Mitterhauser M, Kasper S, Lanzenberger R. Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET. NeuroImage 2009 Apr 1;45(2):598-605. Epub 2008 Dec 9. [2013, IF: 6.132]

50. Witte A. Veronica, Savli M, Holik A, Kasper S, Lanzenberger R.

Regional sex differences in grey matter volume are associated with sex hormones in the young adult human brain. NeuroImage 2010 Jan 15;49(2):1205-1212. Epub 2009 Sep 28. [2013, IF: 6.132]

Section XIV 13/23

51. Windischberger C*, Lanzenberger R*, Stein P, Holik A, Spindelegger C, Moser U, Gerstl F, Fink M, Moser E, Kasper S. (*contributed equally)

Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. NeuroImage 2010;49(2):1161-1170. Epub 2009 Oct 13 [2013, IF: 6.132]

52. Stein P, Baldinger P, Kaufmann U, Rami-Mark C, Hahn A, Höflich A, Kranz GS, Savli

M, Wadsak W, Mitterhauser M, Winkler D, Kasper S, Lanzenberger R. Relation of progesterone and DHEAS serum levels to 5-HT1A receptor binding potential in pre- and postmenopausal women. Psychoneuroendocrinology 2014 Aug;46:52-63. Epub 2014 May 10 [2013, IF: 5.591]

53. Kranz GS, Rami-Mark C, Kaufmann U, Baldinger P, Hahn A, Höflich A, Savli M, Stein P, Wadsak W, Mitterhauser M, Winkler D, Lanzenberger R#, Kasper S. Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl-11C]WAY-100635. (#corresponding author) Psychoneuroendocrinology 2014 July;45:1-10. Epub 2014 March 20 [2013, IF: 5.591]

54. Gryglewski G, Lanzenberger R#, Kranz GS, Cumming P. (#corresponding author). Molecular Imaging: Serotonin transporters are reduced in major depression. Journal of Cerebral Blood Flow & Metabolism 2014 Jul;34(7):1096-103. Epub 2014 May 7 [2013, IF: 5.339]

55. Lanzenberger R, Wadsak W, Spindelegger C, Mitterhauser M, Akimova E, Mien LK, Fink M, Moser U, Savli M, Kranz SG, Hahn A, Kletter K, Kasper S. Cortisol plasma levels in Social Anxiety Disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. International Journal of Neuropsychopharmacology 2010 Oct;13(9):1129-43. Epub 2010 Jun 2 [2013, IF: 5.264]

56. Stein P, Savli M, Wadsak W, Mitterhauser M, Fink M, Spindelegger C, Mien LK, Moser U, Dudczak R, Kletter K, Kasper S, Lanzenberger R. The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-11C]WAY-100635. European Journal of Nuclear Medicine and Molecular Imaging (Eur J Nucl Med Mol Imaging) 2008 Dec;35(12):2159-68. Epub 2008 Jun 10. [2013, IF: 5.217]

57. Lanzenberger R, Mitterhauser M, Kranz GS, Spindelegger C, Wadsak W, Stein P, Moser U, Kletter K, Kasper S. Progesterone level predicts serotonin-1A receptor binding in the male human brain. Neuroendocrinology 2011;94(1):84-8. Epub 2011 May 21. [2013, IF: 4.934]

58. Baldinger P, Hahn A, Mitterhauser M, Kranz G, Friedl M, Wadsak W, Kraus C, Ungersböck J, Hartmann A, Giegling I, Rujescu D, Kasper S, Lanzenberger R. Impact of COMT genotype on serotonin-1A receptor binding investigated with PET. Brain Structure and Function 2014;219:2017–2028. Epub 2013 Aug 9. [2013, IF: 4.567]

59. Kranz GS, Hahn A, Baldinger P, Haeusler D, Philippe C, Kaufmann U, Wadsak W, Savli M, Höflich A, Kraus C, Vanicek T, Mitterhauser M, Kasper S, Lanzenberger R. Cerebral serotonin transporter asymmetry in females, males and male-to-memale transsexuals measured by PET in vivo.

Section XIV 14/23

Brain Structure and Function 2014 Jan;219(1):171-83. Epub 2012 Dec 9. [2013, IF: 4.567]

60. Spindelegger C, Stein P, Wadsak W, Fink M, Mitterhauser M, Moser U, Savli M, Mien LH, Akimova E, Hahn A, Willeit M, Kletter K, Kasper S, Lanzenberger R. Light-dependent alteration of serotonin-1A receptor binding in cortical and subcortical limbic regions in the human brain. World Journal of Biological Psychiatry 2012 Sept;13(6):413-422. Epub 2011 Nov 23 [2013, IF: 4.225]

61. Vyas N, Patel NH, Herscovitch P, Puri BK, Lanzenberger R. Recent developments in neurochemical imaging in schizophrenia: an update Special issue "Molecular basis of antipsychotic drugs: the contribution of neuroimaging” Current Medicinal Chemistry 2013;20(3):351-6. Epub 2012 Nov 14 [2013, IF: 3.715]

62. Saulin A, Savli M, Lanzenberger R. Serotonin and molecular neuroimaging in humans using PET. Amino Acids 2012 Jun; 42(6):2039-57. Epub 2011 Sep 24 [2013, IF: 3.653]

63. Kraus C, Baldinger P, Rami-Mark C, Gryglewski G, Kranz GS, Haeusler D, Hahn A, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Exploration the impact of BDNF Val66Met genotype on serotonin transporter and serotonin-1A receptor binding. PLoS ONE 2014 xx.x. Epub 2014 Sep 4;9(9). [2013, IF: 3.534]

64. Fuchs I, Ansorge U, Huber-Huber C, Höflich A, Lanzenberger R. S-ketamine influences strategic allocation of attention but not exogenous capture of attention Consciousness & Cognition 2015 xxx. Epub 2015 Feb 9 [2013, IF: 3.477]

65. Derntl B, Schöpf V, Kollndorfer K, Lanzenberger R. Menstrual cycle phase and duration of oral contraception intake affect olfactory perception Chemical Senses 2012 Jan;38(1):67-75. Epub 2012 Oct 15 [2013, IF: 3.278]

66. Kranz GS, Kasper S, Lanzenberger R. Reward and the Serotonergic System. (REVIEW) Neuroscience 2010 Apr 14;166(4):1023-1035. Epub 2010 Jan 28. [2013, IF: 3.327]

67. Hahn A, Nics L, Baldinger P, Wadsak W, Savli M, Kraus C, Birkfellner W,

Ungersboeck J, Haeusler D, Mitterhauser M, Karanikas G, Kasper S, Frey R, Lanzenberger R. Application of image-derived and venous input functions in major depression using [carbonyl-11C]WAY-100635. Nuclear Medicine and Biology 2013 Apr; 40(3): 371-7; Epub 2013 Jan 30 [2013, IF: 2.408].

68. Lanzenberger R, Beisteiner R, Prayer D. Discussion of the Brain Atlas for Functional Imaging (BAFI), W.L. Nowinski, A. Thirunavuukarasuu, D.N. Kennedy; Thieme Verlag, Stuttgart, 2000 European Journal of Radiology 2002 Mar;41(3):255-6. [2013, IF: 2.160]

Section XIV 15/23

69. Moser U, Wadsak W, Spindelegger C, Mitterhauser M, Mien LK, Bieglmayer C, Kletter K, Kasper S, Lanzenberger R. Hypothalamic serotonin-1A receptor binding measured by PET predicts the plasma level of dehydroepiandrosterone sulphate in healthy women. Neuroscience Letters 2010 Jun 7;476(3):161-5. Epub 2010 Apr 22. [2013, IF: 2.055]

70. Baldinger P, Lotan A, Frey R, Kasper S, Lerer B, Lanzenberger R. Neurotransmitters and ECT

30.2 Special Issue: Mechanism of Action of ECT (Pascal Sienaert, guest-editor) Journal of ECT 2014 Jun;30(2):116-21. Epub 2014 May 9 [2013, IF: 1.387]

71. Lanzenberger R, Wiest G, Geissler A, Barth M, Ringl H, Wöber C, Gartus A, Baumgartner C, Beisteiner R. FMRI reveals functional cortex in a case of inconclusive Wada testing. Clinical Neurology and Neurosurgery 2005 Feb; 107(2):147-51 [2013, IF: 1.248] 72. Lanzenberger R, Kasper S. NeuroImaging bei schizophrenen Erkrankungen [Neuroimaging in Schizophrenia]. Fortschr Neurol Psychiatr. 2005 Nov;73 Suppl 1:51-9 [2013, IF: 0.762] 73. Hahn A, Kranz G, Sladky R, Ganger S, Windischberger C, Kasper S, Lanzenberger

R Individual diversity of functional brain network economy. Brain Connectivity 2014 xxx. Epub 2014 Nov 20 [2013, IF: 0.000]

74. Lanzenberger R, Hackhofer S, Kranz GS, Kasper S.

Wie viel Gehirn braucht der Affekt? Bildgebende Verfahren und affektive Symptome bei Schizophrenie. (REVIEW) Psychiatrie & Psychotherapie 2010;6/3:133-138 [2013, IF: 0.00]

75. Kasper S, Gryglewski G, Lanzenberger R. Imaging brain circuits in anxiety disorders. Comment Lancet Psychiatry 2014 xxx. Epub 2014 Aug 27 [2013, IF: 0.000] www.thelancet.com/psychiatry. http://dx.doi.org/10.1016/S2215-0366(14)70348-7

B. Co-author (accumulated 2013 IF: 261.4; 73 papers, mean IF: 3.6; descend. order) 1. Akimova E, Lanzenberger R, Kasper S.

The Serotonin-1A receptor in Anxiety disorders. (REVIEW) Biological Psychiatry 2009 Oct 1;66(7):627-35. Epub 2009 May 7. [2013, IF: 9.472]

2. Sladky R, Höflich A, Küblböck M, Kraus C, Baldinger P, Moser E, Lanzenberger R, Windischberger C. Disrupted effective connectivity between the amygdala and orbitofrontal cortex in social anxiety disorder during emotion discrimination revealed by dynamic causal modeling for fMRI. Cerebral Cortex 2014 xx; Epub 2013 Oct 9 [2013, IF: 8.305]

3. Riederer F, Lanzenberger R, Kaya M, Prayer D, Serles W, Baumgartner C Network atrophy in temporal lobe epilepsy – A voxel-based morphometry study. Neurology 2008 Aug 5;71(6):419-25 [2013, IF: 8.303]

Section XIV 16/23

4. Bauer M, Langer O, Dal-Bianco P, Karch R, Brunner M, Abrahim A, Lanzenberger R, Hofmann A, Joukhadar C, Carminati P, Ghirardi O, Piovesan P, Forloni G, Corrado M, Lods N, Dudczak R, Auff E, Kletter K, Müller M. A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer’s disease. Clinical Pharmacology and Therapeutics 2006 Sep;80(3):216-27 [2013, IF: 7.390]

5. Seidel EM, Pfabigan DM, Hahn A, Sladky R, Grahl A, Paul K, Kraus C, Küblböck M, Kranz GS, Hummer A, Lanzenberger R, Windischberger C, Lamm C. Uncertainty during pain anticipation: The adaptive value of preparatory processes. Human Brain Mapping 2014 xx. Epub 2014 Oct 16 [2013, IF: 6.924]

6. Comasco E, Hahn A, Ganger S, Gingnell M, Bannbers E, Oreland L, Wikström J, Epperson NC, Neill J, Lanzenberger R, Sundström-Poromaa I. Emotional fronto-cingulate cortex activation and brain derived neurotrophic factor polymorphism in premenstrual dysphoric disorder. Human Brain Mapping 2014 Sep;35(9):4450-8. Epub 2014 Feb 25 [2013, IF: 6.924]

7. Edward V, Windischberger C, Cunnington R, Erdler M, Lanzenberger R, Mayer D,

Endl W, Beisteiner R. Quantification of fMRI artifact reduction by a novel plaster cast head holder. Human Brain Mapping 2000 Nov;11(3):207-13 [2013, IF: 6.924]

8. Hahn A, Lanzenberger R, Wadsak W, Spindelegger C, Moser U, Mien LK,

Mitterhauser M, Kasper S. Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders. Journal of Neuroscience 2010 Oct 27; 30(43):14482-89 [2013, IF: 6.747]

9. Sladky R, Spies M, Hoffmann A, Kranz GS, Hummer A, Gryglewski G, Lanzenberger R, Windischberger C, Kasper S. (S)-citalopram influences amygdala modulation in healthy subjects: a randomized placebo-controlled double-blind fMRI study using dynamic causal modeling. NeuroImage 2015 xxx. Epub 2014 Dec 20. [2013, IF: 6.132]

10. Küblböck M, Woletz M, Höflich A, Sladky R, Kranz GS, Hoffmann A, Lanzenberger R, Windischberger C. Stability of low-frequency fluctuation amplitudes in prolonged resting-state fMRI. NeuroImage 2014 xxx. Epub 2014 Sep 22 [2013, IF: 6.132]

11. Pfabigan DM, Seidel EM, Sladky R, Hahn A, Paul K, Grahl A, Küblböck M, Kraus K, Hummer A, Kranz GS, Windischberger C, Lanzenberger R, Lamm C. P300 amplitude variation is related to ventral striatum BOLD response during gain and loss anticipation: An EEG and fMRI experiment. NeuroImage 2014 Aug 1;96:12-21. Epub 2014 Apr 6 [2013, IF: 6.132]

12. Baldinger P*, Kranz GS*, Haeusler D, Savli M, Spies M, Philippe C, Hahn A, Höflich A, Wadsak W, Mitterhauser M, Lanzenberger R, Kasper S. (*contributed equally) Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET. NeuroImage 2014 Feb 13; 88:252-262. Epub 2013 Oct 11 [2013, IF: 6.132]

13. Kalcher K, Boubela RN, Huf W, Biswal B, Baldinger P, Sailer U, Filzmoser P, Kasper

S, Lamm C, Lanzenberger R, Moser E, Windischberger C. RESCALE: Voxel-specific task-fmri scaling using resting state fluctuation amplitude.

Section XIV 17/23

Neuroimage 2013 Apr 15; 70:80-88. Epub 2012 Dec 21 [2013, IF: 6.132]

14. Schöpf V, Windischberger C, Robinson S, Kasess C, Fischmeister F, Lanzenberger R, Albrecht J, Kleemann A, Kopietz R, Wiesmann M, Moser E. Model-free fMRI group analysis using FENICA. NeuroImage 2011 Mar 1;55(1):185-93. Epub 2010 Nov 13 [2013, IF: 6.132]

15. Weissenbacher A, Kasess C, Gerstl F, Lanzenberger R, Moser E, Windischberger C.

Correlations and Anticorrelations in Resting-State Functional Connectivity MRI: A Quantitative Comparison of Preprocessing Strategies. NeuroImage 2009 Oct 1; 47(4):1408-1416. Epub 2009 May 13 [2013, IF: 6.132]

16. Kasess C, Windischberger C, Cunnington R, Lanzenberger R, Pezawas L, Moser E. The suppressive influence of SMA on M1 in motor imagery revealed by fMRI and dynamic causal modeling. NeuroImage 2008 Apr 1;40(2):828-37. Epub 2007 Dec 8 [2013, IF: 6.132]

17. Beisteiner R, Windischberger W, Lanzenberger R, Edward V, Cunnington R,

Erdler M, Gartus A, Streibl B, Moser E, Deecke L. Finger Somatotopy in Human Motor Cortex NeuroImage. 2001 Jun; 13(6): 1016-26 [2013, IF: 6.132]

18. Geissler A, Lanzenberger R, Barth M, Tahamtan A, Milakara D, Gartus A, Beisteiner, R.

Influence of fMRI smoothing procedures on replicability of fine scale motor localization. NeuroImage 2005 Jan 15; 24(2): 323-31 [2013, IF: 6.132]

19. Toffoletto S, Lanzenberger R, Gingnell M, Sundström-Poromaa I, Comasco E. Emotional and cognitive functional imaging of estrogen and progesterone effects in the female human brain: a systematic review. REVIEW Psychoneuroendocrinology 2014 xxx. Epub 2014 Aug 13;50C:28-52 [2013, IF: 5.591]

20. Roessler K, Donat M, Lanzenberger R, Novak K, Geissler A, Gartus A, Tahamtan AR, Milakara D, Czech T, Barth M, Knosp E, Beisteiner R. Evaluation of preoperative high magnetic field motor functional MRI (3 Tesla) in glioma patients by navigated electrocortical stimulation and postoperative outcome J Neurol Neurosurg Psychiatry 2005 Aug;76(8):1152-7 [2013, IF: 5.580]

21. Fabbri C, Marsano A, Albani D, Chierchia A, Calati R, Drago A, Crisafulli C, Calabrò M, Kasper S, Lanzenberger R, Zohar J, Juven-Wetzler A, Souery D, Montgomery S, Mendlewicz J, Serretti A. PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogenomics Journal 2014 Oct;14(5):463-72. Epub 2014 Apr 8 [2013, IF: 5.513]

22. Kautzky A, Baldinger P, Souery D, Montgomery S, Mendlewicz J, Zohar J, Serretti A, Lanzenberger R, Kasper S. The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment resistant depression. European Neuropsychopharmacology 2015 xxx. Epub xxx [2013, IF: 5.395]; in press

Section XIV 18/23

23. Höfer P, Lanzenberger R, Kasper S. Testosterone in the brain: Neuroimaging findings and the potential role for psychopharmacology. REVIEW European Neuropsychopharmacology 2013 Feb; 23(2):79-88. Epub 2012 May 10 [2013, IF: 5.395]

24. Attarbaschi T, Sacher J, Geiss-Granadia T, Klein N, Mossaheb N, Lanzenberger R, Asenbaum S, Dudczak R, Kasper S, Tauscher J.

Striatal D2 receptor occupancy in bipolar patients treated with olanzapine. European Neuropsychopharmacology 2007 Jan 15; 17(2):102-7 [2013, IF: 5.395]

25. Baldinger P, Höflich AS, Mitterhauser M, Hahn A, Rami-Mark C, Spies M, Wadsak W,

Lanzenberger R, Kasper S. Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. The International Journal of Neuropsychopharmacology 2015 xxxx. Epub 2014 Oct 31 [2013, IF: 5.264]

26. Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. The International Journal of Neuropsychopharmacology 2013 Apr;16(3):557-74. Epub 2012 Aug 29:1-18 [2013, IF: 5.264]

27. Sacher J, Asenbaum S, Klein N, Geiss-Granadia T, Mossaheb N, Poetzi C, Attarbaschi T, Lanzenberger R, Spindelegger C, Rabas A, Heinze G, Dudczak R, Kasper S, Tauscher J.

Binding kinetics of 123I[ADAM] in healthy controls: a selective SERT radioligand. The International Journal of Neuropsychopharmacology 2007 Apr; 10(2): 211-8 [2013, IF: 5.264]

28. Haeusler D, Kuntner C, Nics L, Savli M, Zeilinger M, Wanek T, Karagiannis P, Lanzenberger RR, Langer O, Shanab K, Spreitzer H, Wadsak W, Hacker M, Mitterhauser M. [18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents. European Journal of Nuclear Medicine and Molecular Imaging 2015 xxx. Epub 2015 Jan 20 [2013, IF: 5.217]

29. Riederer F, Marti M, Luechinger R, Lanzenberger R, von Meyenburg J, Gantenbein AR, Pirrotta R, Gaul C, Kollias S, Sándor PS. Grey matter changes associated with medication-overuse headache: correlations with disease related disability and anxiety. World Journal of Biological Psychiatry 2012 Oct;13(7):517-25. Epub 2012 Jul 2 [2013, IF: 4.225]

30. Winkler D, Pjrek E, Lanzenberger R, Baldinger P, Eitel D, Kasper S, Frey R. Actigraphy in patients with treatment-resistant depression undergoing electroconvulsive therapy. Journal of Psychiatric Research 2014; 57:96-100; Epub 2014 Jun 24 [2013, IF: 4.092]

Section XIV 19/23

31. Klein N, Sacher J, Geiss-Granadia T, Attarbaschi T, Mossaheb N, Lanzenberger R, Pötzi C, Holik A, Spindelegger C, Asenbaum S, Dudczak R, Tauscher J, Kasper S. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.

Psychopharmacology (Berl). 2006 Oct;188(3):263-72 [2013, IF: 3.988] 32. Klein N, Sacher J, Geiss-Granadia T, Mossaheb N, Attarbaschi T, Lanzenberger R,

Spindelegger C, Holik A, Asenbaum S, Dudczak R, Tauscher J, Kasper S. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology (Berl). 2007 Apr; 191(2): 333-9 [2013, IF: 3.988]

33. Beisteiner R, Gartus A, Erdler M, Mayer D, Lanzenberger R, Deecke L. Magnetoencephalography indicates finger motor somatotopy.

Eur J Neuroscience 2004 Jan; 19(2): 465-72. [2013, IF: 3.669]

34. Sladky R, Höflich A, Atanelov J, Kraus C, Baldinger P, Moser E, Lanzenberger R, Windischberger C. Increased neural habituation in the amygdala and orbitofrontal cortex in social anxiety disorder revealed by fMRI. PLoS ONE 2012;7(11):e50050. Epub 2012 Nov 29 [2013, IF: 3.534]

35. Scharinger C, Rabl U, Kasess CH, Meyer BM, Hofmaier T, Diers K, Bartova L, Pail G, Huf W, Uzelac Z, Hartinger B, Kalcher K, Perkmann T, Haslacher H, Meyer-Lindenberg A, Kasper S, Freissmuth M, Windischberger C, Willeit M, Lanzenberger R, Esterbauer H, Brocke B, Moser E, Sitte H, Pezawas L. Platelet serotonin transporter function predicts default-mode network activity. PLoS ONE 2014 Mar 25;9(3):e92543. [2013, IF: 3.534]

36. Pfabigan DM, Seidel EM, Paul K, Grahl A, Sailer U, Lanzenberger R, Windischberger C, Lamm C. Context-sensitivity of the feedback-related negativity for zero-value feedback outcomes Biological Psychology 2015 xxx. Epub 2014 Dec 22;104C:184-192 [2013, IF: 3.473]

37. Höflich A, Baldinger P, Savli M, Lanzenberger R, Kasper S. Imaging treatment effects in depression. REVIEW

Reviews in the Neurosciences 2012; 23(3): 227-52 Epub DOI 10.1515/revneuro-2012-0038 [2013, IF: 3.314]

38. Kasper S, Sacher J, Klein N, Mossaheb N, Attarbaschi-Steiner T, Lanzenberger R,

Spindelegger C, Asenbaum S, Holik A, Dudczak R. Differences in the dynamics of SERT occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol. 2009 May;24(3):119-25 [2013, IF: 3.098]

39. Philippe C, Ungersboeck J, Schirmer E, Zdravkovic M, Nics L, Zeilinger M, Shanab K, Lanzenberger R, Karanikas G, Spreitzer H, Viernstein H, Mitterhauser M, Wadsak W. [18F]FE@SNAP — A new PET tracer for the melanin concentrating hormone receptor 1 (MCHR1): microfluidic and vessel-based approaches.

Section XIV 20/23

Bioorganic & Medicinal Chemistry 2012 Oct 1;20(19):5936-40. Epub 2012 Aug 7 [2013, IF: 2.951]

40. Rami-Mark C, Zhang MR, Mitterhauser M, Lanzenberger R, Hacker M, Wadsak W. [18F]FMeNER-D2: Reliable fully-automated synthesis for visualization of the norepinephrine transporter. Nuclear Medicine and Biology 2013;40:1049-54. Epub 2013 Oct 4. doi:pii: S0969-8051(13)00174-1 [2013, IF: 2.408]

41. Mitterhauser M, Toegel S, Wadsak W, Lanzenberger R, Mien LK, Kuntner C, Wanek

T, Harald Eidherr H, Ettlinger DE, Viernstein H, Kluger R, Dudczak R, Kletter K Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP.

Nuclear Medicine and Biology 2007 May; 34(4):391-97 [2013, IF: 2.408] 42. Wadsak W, Mien LK, Shanab K, Ettlinger DE, Haeusler D, Sindelar K, Lanzenberger

R, Spreitzer H, Viernstein H, Keppler BK, Dudczak R, Kletter K, Mitterhauser M. Preparation and first evaluation of [18F]FE@SUPPY: a new PET tracer for the adenosine A3 receptor. Nuclear Medicine and Biology 2008 Jan;35(1):61-6 [2013, IF: 2.408]

43. Ungersboeck J, Philippe C, Mien LK, Haeusler D, Shanab K, Lanzenberger R, Spreitzer H, Keppler B, Dudczak R, Kletter K, Mitterhauser M, Wadsak W. Microfluidic preparation of [18F]FE@SUPPY and [18F]FE@SUPPY:2 – comparison with conventional radiosyntheses. Nuclear Medicine and Biology 2011 Apr;38(3):427-34. Epub 2010 Dec 3 [2013, IF: 2.408]

44. Haeusler D, Nics L, Mien LK, Ungersboeck J, Lanzenberger R, Shanab K, Sindelar KM, Viernstein H, Wagner KH, Dudczak R, Kletter K, Wadsak W, Mitterhauser M. [18F]FE@SUPPY and [18F]FE@SUPPY:2 - Metabolic considerations Nuclear Medicine and Biology 2010 May;37(4):421-6. Epub 2010 Mar 6 [2013, IF: 2.408]

45. Ungersboeck J, Richter S, Collier L, Mitterhauser M, Karanikas G, Lanzenberger R, Dudczak R, Wadsak W. Radiolabelling of [18F]altanserin – a microfluidic approach. Nuclear Medicine and Biology 2012 Oct;39(7):1087-92. Epub 2012 May 23 [2013, IF: 2.408]

46. Mark C, Bornatowicz B, Mitterhauser M, Hendl M, Nics L, Haeusler D, Lanzenberger R, Berger M, Spreitzer H, Wadsak W. Development and automation of a novel NET-PET tracer: [11C]Me@APPI Nuclear Medicine and Biology 2013 Feb; 40(2):295-303. Epub 2012 Dec 21 [2013, IF: 2.408]

47. Sladky R, Baldinger P, Kranz GS, Tröstl J, Höflich A, Lanzenberger R, Moser E, Windischberger C. High-resolution functional MRI of the human amygdala at 7 T. European Journal of Radiology 2013 May;82(5):728-33. Epub 2011 Dec 3 [2013, IF: 2.160]

48. Assem-Hilger E, Lanzenberger R, Savli M, Wadsak W, Mitterhauser M, Mien LK, Stögmann E, Baumgartner C, Kletter K, Asenbaum S.

Central Serotonin 1A receptor binding in temporal lobe epilepsy: a [carbonyl-(11)C]WAY-100635 PET study.

Section XIV 21/23

Epilepsy & Behavior 2010 Nov;19(3):467-73. Epub 2010 Sep 17. [2013, IF: 2.061]; 49. Erdler M, Windischberger C, Lanzenberger R, Edward V, Gartus A, Deecke L,

Beisteier R. Dissociation of supplementary motor area and primary motor cortex in human subjects when comparing index and little finger movements with functional magnetic resonance imaging. Neurosci Lett. 2001 Nov 2;313(1-2):5-8. [2013, IF: 2.055]

50. Beisteiner R, Lanzenberger R, Novak K, Edward V, Windischberger C, Erdler M,

Cunnington R, Gartus A, Streibl B, Moser E, Czech T, Deecke L. Improvement of presurgical patient evaluation by generation of functional MR risk maps. Neurosci Lett. 2000 Aug 18;290(1):13-6. [2013, IF: 2.055]

51. Windischberger W, Cunnington R, Lamm C, Lanzenberger R, Langenberger H,

Deecke L, Bauer H, Moser E. Time-resolved Analysis of fMRI signal changes using Brain Activation Movies Journal of Neuroscience Methods 2008 Mar 30; 169(1): 222-30 [2013, IF: 1.959]

52. Schöpf V, Kasess CH, Lanzenberger R, Fischmeister F, Windischberger C, Moser E.

Fully Explorative Network ICA (FENICA) on resting-state fMRI data. Journal of Neuroscience Methods 2010 Oct 15;192(2):207-13. Epub 2010 Aug 3 [2013, IF: 1.959]

53. Haeusler D, Mitterhauser M, Mien LK, Shanab K, Lanzenberger R, Schirmer E,

Ungersboeck J, Nics L, Spreitzer H, Viernstein H, Dudczak R, Kletter K, Wadsak W. Radiosynthesis of a novel potential adenosine A3 receptor ligand, 5-ethyl 2,4-diethyl-3-((2-[18F]fluoroethyl)sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([18F]FE@SUPPY:2). Radiochimica Acta 2009; 97: 753-8 [2013, IF: 1.411]

54. Wadsak W, Mien LK, Ettlinger DE, Lanzenberger R, Haeusler D, Dudczak R, Kletter K, Mitterhauser M.

Simple and fully automated preparation of [carbonyl-11C]WAY-100635. Radiochimica Acta 2007, 95, 417-22 [2013, IF: 1.411]

55. Wadsak W, Mien LK, Ettlinger DE, Feitscher S, Lanzenberger R, Marton J, Dudczak

R, Kletter K, Mitterhauser M. Preparation and radiosynthesis of [18F]FE@CFN (2-[18F]fluoroethyl 4-[N-(1- oxopropyl)-N- phenylamino]-1-(2-phenylethyl)-4-piperidinecarboxylate): a potential µ- opioid receptor imaging agent.

Radiochimica Acta 2007; 95, 33-8 [2013, IF: 1.411] 56. Schöpf V, Windischberger C, Kasess CH, Lanzenberger R, Moser E.

Group ICA analysis of resting-state data: a comparison. MAGMA (Magnetic Resonance Materials in Physics, Biology and Medicine) 2010 Dec;23(5-6):317-25. Epub 2010 Jun 3 [2013, IF: 1.353]

57. Philippe C, Nics L, Zeilinger M, Schirmer E, Spreitzer H, Karanikas G, Lanzenberger

R, Viernstein H, Wadsak W, Mitterhauser M. Preparation and first preclinical evaluation of [18F]FE@SNAP: a potential PET tracer for the melanin-concentrating hormone receptor-1 (MCHR1). Scientia Pharmaceutica 2013 Jul 1;81(3):625-639 [2013, IF: 1.088]

Section XIV 22/23

58. Philippe C, Zeilinger M, Mitterhauser M, Dumanic M, Lanzenberger R, Hacker M, Wadsak W. Parameter evaluation and fully-automated radiosynthesis of [11C]harmine for imaging of MOA-A for clinical trials. Applied Radiation and Isotopes 2015 xxx. Epub 2015 Jan 7;97C:182-187 [2013, IF: 1.056]

59. Nics L, Hahn A, Zeilinger M, Vraka C, Ungersboeck J, Haeusler D, Hartmann S, Wagner KH, Dudczak R, Lanzenberger R, Wadsak W, Mitterhauser M. Quantification of the radio-metabolites of the serotonin-1A receptor radioligand [carbonyl-11C]WAY-100635 in human plasma: an HPLC-assay which enables measurement of two patients in parallel. Applied Radiation Isotopes 2012 Dec;70(12):2730-6. Epub 2012 Sep 13 [2013 IF: 1.056]

60. Ungersboeck J, Philippe C, Haeusler D, Mitterhauser M, Lanzenberger R, Dudczak R, Wadsak W. Optimization of [11C]DASB-synthesis: vessel-based and flow-through microreactor methods. Applied Radiation and Isotopes 2012 Nov; 70(11): 2615-2620. Epub 2012 Aug 9 [2013, IF: 1.056]

61. Philippe C, Schirmer E, Mitterhauser M, Shanab K, Lanzenberger R, Karanikas G,

Spreitzer H, Viernstein H, Wadsak W. Radiosynthesis of [11C]SNAP-7941 – the first PET-tracer for the melanin concentrating hormone receptor 1 (MCHR1). Applied Radiation and Isotopes 2012;70(10):2287-94. Epub 2012 Jul 20 [2013, IF: 1.056]

62. Haeusler D, Mien LK, Nics L, Ungersboeck J, Philippe C, Lanzenberger R, Kletter K,

Dudczak R, Mitterhauser M, Wadsak W. Simple and rapid preparation of [11C]DASB with high quality and reliability for routine applications. Applied Radiation and Isotopes 2009 Sep; 67(9):1654-60. Epub 2009 Mar 20. [2013, IF: 1.056]

63. Rami-Mark C, Ungersboeck J, Haeusler D, Nics L, Philippe C, Mitterhauser M, Willeit M, Lanzenberger R, Karanikas G , Wadsak W. Reliable set-up for in-loop 11C-carboxylations using Grignard reactions for the preparation of [carbonyl-11C]WAY-100635 and [11C]-(+)-PHNO. Applied Radiation and Isotopes 2013 Aug 3;82C:75-80 [2013, IF: 1.056]

64. Baldinger P, Kranz G, Höflich A, Savli M, Stein P, Lanzenberger R, Kasper S.

Hormonersatztherapie und deren Wirkung auf Psyche und Gehirn. REVIEW [The effects of hormone replacement therapy on mind and brain.] Nervenarzt 2013 Jan;84(1):14-9. Epub 2012 Feb 10 [2013, IF: 0.862]

65. Dold M, Aigner M, Lanzenberger R, Kasper S.

Effektivität einer Augmentationstherapie von Antipsychotika und Serotonin-Wiederaufnahmehemmern bei therapieresistenten Zwangsstörungen – eine Meta-Analyse doppelblinder, randomisierter, placebokontrollierter Studien. [Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder - a meta-analysis of double-blind, randomised, placebo-controlled trials].

Section XIV 23/23

Fortschritte der Neurologie und Psychiatrie 2011 Aug;79(8):453-66. Epub 2011 Aug 1 REVIEW [2013, IF: 0.762]

66. Fink M, Akimova E, Spindelegger C, Hahn A, Lanzenberger R, Kasper S.

Social Anxiety Disorder: Epidemiology, Biology and Treatment Psychiatria Danubina 2009 Dec;21(4):533-42 [2013, IF: 0.653]

67. Robinson S, Hoheisel B, Windischberger C, Habel U, Lanzenberger R, Moser E

FMRI of the Emotions: Towards an Improved Understanding of Amygdala Function. Current Medical Image Review 2005; Vol. 1(2): 115-129, [2013, IF: 1.059]

68. Mitterhauser M, Haeusler D, Mien LK, Ungersboeck J, Nics L, Lanzenberger R, Sindelar K, Viernstein H, Dudczak R, Kletter K, Wadsak W. Automatisation and first evaluation of [18F]FE@SUPPY:2, an alternative PET-Tracer for the Adenosine A3 Receptor: A Comparison with [18F]FE@SUPPY. The Open Nuclear Medicine Journal (TONMEDJ) 2009;1:15-23 [2013, IF: 0.0];

69. Fink M, Moser U, Akimova E, Savli R, Lanzenberger R, Kasper S. Auf einen Blick: Multimodale Bildgebung bei einer organischen depressiven Störung mittels fMRT und PET. Journal für Neurologie, Neurochirurgie und Psychiatrie 2011; 12(2) [2013, IF: 0.0]

70. Stein P, Lanzenberger R, Kasper S, Aigner M.

Psychiatrische Manifestation einer milden Form der limbischen Encephalitis. Journal für Neurologie, Neurochirurgie und Psychiatrie 2012; 12(x) [2013, IF: 0.0]

71. Baldinger P, Hahn A, Friedl M, Kranz GS, Ungersböck J, Höflich A, Mitterhauser M,

Rujescu D, Wadsak W, Lanzenberger R, Kasper S. Einfluss des HTR1A Polymorphismus rs878567 auf das Serotonin-1A Bindungspotenzial in vivo. Journal für Neurologie, Neurochirurgie & Psychiatrie 2012; 12(x) [2013, IF: 0.0]

72. Höflich A, Baldinger P, Lanzenberger R, Kasper S, Winkler D. Das Charles Bonnet Syndrom. REVIEW Journal für Neurologie, Neurochirurgie & Psychiatrie 2012; 13(4) [2013, IF: 0.0]

73. Kasper S, Schosser A, Lanzenberger R. Bildgebung und Genetik in der Psychiatrie – quo vadis? REVIEW Serie „Trends & Perspektiven in der Psychiatrie“ Journal für Neurologie, Neurochirurgie und Psychiatrie 2012; 13(4) [2013, IF: 0.0]